Market revenue in 2023 | USD 438.4 million |
Market revenue in 2030 | USD 710.0 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Anti- inflammatories |
Fastest growing segment | Combination therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Anti- inflammatories, Bronchodilators, Combination therapy |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, GSK PLC, Merck & Co Inc, Roche Holding AG, AstraZeneca PLC, Boehringer Ingelheim, Sanofi SA, Koninklijke Philips NV, BD, Corvus Pharmaceuticals Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to asthma therapeutics market will help companies and investors design strategic landscapes.
Anti- inflammatories was the largest segment with a revenue share of 62.68% in 2023. Horizon Databook has segmented the Japan asthma therapeutics market based on anti- inflammatories, bronchodilators, combination therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most technologically advanced countries in Asia Pacific. Its asthma therapeutics market is expected to grow rapidly over the forecast period due to high government spending to reduce the disease burden. In Japan, around 36.4 million i.e., 29.1% of the population, is aged 65 years and above and the figure is expected to rise to 35.3% by 2040.
The rapidly aging population and increasing expectations for improved quality of life in Japan are propelling market growth. In addition, geriatric population is more susceptible to respiratory diseases and the incidence of asthma & COPD is also increasing. This is leading to an increased demand for novel treatment options.
In recent decades, Japan’s average life expectancy has improved due to the improvements in environmental sanitation and medical care. However, several elderly COPD patients develop a wide range of comorbidities, and limitations in daily activities leading to frailty and increased social & economic difficulties.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan asthma therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan asthma therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account